The article discusses a significant rise in poison control calls involving semaglutide (Ozempic and Wegovy) following its FDA approval for weight management in 2021.Researchers linked the surge in calls to accidental dosing mistakes rather than intentional misuse.

Jordan Miller, an undergraduate student at the University of Texas at San Antonio, collaborated with experts to analyze national poison control data, revealing that GLP-1RA-related calls nearly doubled after 2021, with semaglutide being the most common culprit.Most incidents involved therapeutic errors, such as daily dosing instead of weekly injections or starting with the highest dose immediately.The study highlights the need for better patient education to prevent these avoidable incidents.The findings were published in the Journal of Medical Toxicology and featured in Significance magazine.

The research underscores how data science can uncover public health trends and emphasizes the importance of proper medication education to mitigate risks associated with semaglutide use.